TruWealth Advisors LLC Has $842,000 Stock Position in Stryker Corporation $SYK

TruWealth Advisors LLC raised its holdings in Stryker Corporation (NYSE:SYK) by 4.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,127 shares of the medical technology company’s stock after buying an additional 95 shares during the quarter. TruWealth Advisors LLC’s holdings in Stryker were worth $842,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in SYK. GAMMA Investing LLC lifted its stake in Stryker by 43,226.8% in the first quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company’s stock valued at $772,390,000 after buying an additional 2,070,133 shares during the period. Nuveen LLC acquired a new position in Stryker in the first quarter valued at approximately $558,075,000. Price T Rowe Associates Inc. MD lifted its stake in Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after buying an additional 1,021,496 shares during the period. Alliancebernstein L.P. lifted its stake in Stryker by 66.7% in the first quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock valued at $511,152,000 after buying an additional 549,643 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Stryker in the fourth quarter valued at approximately $154,140,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Down 1.4%

Shares of Stryker stock opened at $383.32 on Friday. The stock has a fifty day simple moving average of $388.98 and a 200 day simple moving average of $379.57. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The company has a market capitalization of $146.55 billion, a P/E ratio of 50.77, a price-to-earnings-growth ratio of 2.80 and a beta of 0.93. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.07 by $0.06. The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, sell-side analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio is 44.50%.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on SYK. Evercore ISI upped their target price on Stryker from $390.00 to $415.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. BTIG Research reaffirmed a “buy” rating on shares of Stryker in a research report on Monday, July 14th. Truist Financial set a $415.00 target price on Stryker and gave the stock a “hold” rating in a research report on Monday, August 4th. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research report on Friday, July 18th. Finally, Needham & Company LLC upped their target price on Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average target price of $431.42.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Viju Menon sold 500 shares of the company’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.